No insider purchase over the last 90 days. The latest, by 고정재, was filed 22 May 2026.
Chabiotech Co.,Ltd.: what insiders have been doing
Chabiotech Co.,Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). The last twelve months, up to 31 October 2026, brought 20 filings signed by 10 insiders.
On the market, 2 insiders bought (2 purchases) while 4 insiders sold (11 sales totalling €965k). No amount is published for 9 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €650k, sold by 차광렬 and made public on 11 March 2026 (0.13% of market cap).
The latest purchase dates back some time: it was published 171 days ago, on 22 May 2026. The median gap between a trade and its publication by DART (FSS) is 6 days. Until a filing is published, the market cannot know about the trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
With 20 filings in twelve months, the company is more active than the median of 7 filings across the 2,655 companies we follow on the same exchange. Looking back to 2021, when coverage begins, insiders filed 13 purchases and 14 sales.
In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySale+6 other insiders
Since the insiders bought
- -67.5%Entry ₩20,750 · Close 30 Oct 2026 ₩6,750
- +39.6%Entry ₩13,250 · Close at T+365 ₩18,500
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- ●Executives0DART
- 1,000 sharesShareKRXDART:20260701000609
- ●Executives0DART
- 500 sharesShareKRXDART:20260609000383
- 12,500 sharesShareKRXDART:20260522000484Canonical exit: 20 Aug 2026 (T+90)
- 12,500 shares0.024% mcap100.0% of flowKRXDART:20260506000531
- 3,903 shares@ ₩13,470.000.016% mcap100.0% of flowShareKRXDART:20260401004203
- 15,183 shares0.033% mcap19.2% of flowKRXDART:20260401004267
- ●Executives0DART
- ●Executives0DART
- 61,189 shares0.13% mcap76.8% of flowKRXDART:20260311004401
- 3,000 shares0.0069% mcap4.0% of flowKRXDART:20260305001332
- 11,868 sharesKRXDART:20260210000775
- 2,759 sharesShareKRXDART:20260210000754
- 7,809,448 sharesKRXDART:20260206001458Canonical exit: 1 May 2026 (T+90)
- 8,000 sharesKRXDART:20260202001121
- 0KRXDART:20260105000345
- ●Executives0DART
- 7,492 sharesKRXDART:20251218000321
- 1,860 sharesKRXDART:20251205000414
- ●Executives0DART
- ●Executives0DART
25 of 103 declarations
About Chabiotech Co.,Ltd.
차바이오텍 is a company specializing in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative therapies and biopharmaceutical solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
